47 results about "Hepatic metastasis" patented technology

The invention discloses an intestinal cancer metastasis prediction method and device based on spatial omics, a medium and equipment, and the method comprises the steps: collecting original multi-omics data, and carrying out modal alignment and quality control processing to obtain pre-processed multi-omics data comprising second spatial transcriptome data, second single-cell RNA sequencing data and second pathological image data; performing cross-modal semantic embedding on the second spatial transcriptome data based on the second single-cell RNA sequencing data to generate a spatial enhanced expression profile; performing multi-scale graph construction on the second spatial transcriptome data and the second pathological image data, and extracting spatial heterogeneity features; inputting the spatial enhancement expression spectrum and the spatial heterogeneity features into a pre-trained metastasis risk prediction model, and outputting a liver metastasis probability spatial heat map and a key driving feature list; and finally generating a clinical prediction report containing high-risk area positioning. According to the method, through dynamic optimization of spatial resolution and multi-scale feature collaborative modeling, the sensitivity of early transfer detection is remarkably improved.

The application discloses a multi-omics pathological analysis system and method for predicting the risk of colorectal liver metastasis, relates to the technical field of biomedical and cancer diagnosis, and comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; the application realizes comprehensive and accurate prediction of the risk of colorectal liver metastasis by integrating multi-omics data, including single-cell data sets, spatial transcriptome data, batch RNA-seq data, clinical data and whole slide image WSIs; the cross-dimension data fusion and analysis not only improve the accuracy and reliability of prediction, but also provide a powerful tool for in-depth exploration of the molecular mechanism of tumor occurrence, development and metastasis, especially in the cell analysis module, identification and analysis of the malignant cell subpopulation LMTMCs triggering liver metastasis can reveal cell subtypes and molecular characteristics closely related to liver metastasis, thereby providing a scientific basis for formulating a personalized treatment plan.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention belongs to the technical field of tumor prognosis prediction, and relates to a colorectal cancer allotropic liver metastasis prediction method and system.The method comprises the steps that colorectal adenocarcinoma cases are collected, the volume of an intra-tumor region-of-interest is delineated and automatically expanded to generate the volume of a peritumor region-of-interest, image omics characteristics are extracted through a pyradiomics packet, core omics characteristics are screened out, and the colorectal cancer allotropic liver metastasis prediction result is obtained. The method comprises the following steps: respectively constructing an intratumoral model and a peritumoral model, analyzing and integrating intratumoral and peritumoral core omics characteristics through logistic regression to form a combined radiomics model, integrating the combined radiomics model and clinical risk factors, establishing a column diagram for predicting the non-hepatic metastasis lifetime, and dividing patients into a low-risk group and a high-risk group according to a column diagram score threshold value; according to the method, LMFS prediction results of 1-5 years can be quickly output, and 0.6911 is set as a standardized risk stratification cut-off value so as to support risk stratification and personalized treatment decision of a patient.

The invention belongs to the technical field of biomedicine, and particularly relates to a flora marker for predicting colorectal cancer liver metastasis and application of the flora marker. According to the present invention, the bacterial group marker is the combination of Acinetobacter, Streptococcus, Pseudomonas, Brevundimonas and Sphingomonas, and the bacterial group marker combination provides extremely high specificity (95.29%) and sensitivity (91.43%) when the early liver metastasis of colorectal cancer is predicted, such that the liver metastasis risk of the patient can be accurately assisted in the determination, and the early liver metastasis risk of the colorectal cancer can be accurately determined; the method has the advantages that reliable basis is provided for clinical decision making, the colorectal cancer liver metastasis can be predicted only by taking the abundance of the specific bacteria as an input index, the method is not limited by specific measurement means, and dependence on a detection technology is greatly reduced.

This invention discloses the application of a branched-chain amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (valine, isoleucine, and leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the transcriptional expression of its target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver metastasis effect. This invention provides a novel dietary intervention strategy and drug target for the treatment of liver metastases of tumors.

A polypeptide specifically blocking the binding of ACVR1C to GREM1 is provided. The small-molecule polypeptide interferes with or blocks the binding of GREM1 to ACVR1C in vitro and in vivo. The liver metastasis of colon cancer in mice in a treatment group is significantly lowered, which indicates that the small-molecular polypeptide achieves the blocking of the liver metastasis of colon cancer.

The present application relates to the application of an oncolytic virus carrying interleukin 10 in the field of colorectal cancer liver metastasis. The present application provides the use of a recombinant oncolytic virus in the preparation of a drug for treating colorectal cancer liver metastasis, wherein the recombinant oncolytic virus expresses interleukin 10. The recombinant oncolytic virus provided in the present application can overcome the immune clearance of the virus and the immunosuppression of the liver metastasis in the treatment of colorectal cancer liver metastasis, thereby improving the treatment effect of colorectal cancer liver metastasis.

The present invention belongs to the field of microorganisms, and particularly relates to the preparation and application of postbiotics of Lactobacillus plantarum ZJUIDS15 for preventing and treating colon cancer. The preparation method of the postbiotics of Lactobacillus plantarum ZJUIDS15 is as follows: after the fermentation supernatant of Lactobacillus plantarum ZJUIDS15 (CGMCC NO. 26120) is inactivated, it is concentrated by freezing to obtain the postbiotics of Lactobacillus plantarum ZJUIDS15. The postbiotics of Lactobacillus plantarum ZJUIDS15 have antibacterial activity and antioxidant capacity, and can relieve the peritoneal metastasis ability and liver metastasis ability of colorectal cancer cells after gavage treatment.

The present application relates to the field of animal model construction, and in particular to a melanoma liver metastasis model construction method, which uses a spleen injection method to construct a human melanoma A375-M1 cell line liver metastasis model, and is identified in vivo by PET-CT and MRI, and is identified ex vivo by Bouin's and H&E.The human melanoma liver metastasis tumor model constructed by the present application has the advantages of short construction time, simple method and 100% modeling success rate.This metastasis model simulates the development process and pathological characteristics of melanoma liver metastasis, solves the problem of the lack of an ideal animal model for human melanoma during liver metastasis, and helps to explore and screen the development of anti-liver metastasis drugs for human melanoma, and plays a positive promoting role in new strategies for anti-melanoma liver metastasis.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

The invention belongs to the field of biological medicine, and particularly relates to application of nicotinic acid and derivatives thereof in prevention or treatment of colorectal cancer growth and metastasis. It is found for the first time that nicotinic acid and novel derivatives thereof can effectively and remarkably inhibit proliferation, migration and invasion of colorectal cancer cells, and can inhibit growth and liver metastasis of the colorectal cancer cells in a mouse model. Experiments prove that the medicine reagent prepared from the nicotinic acid or the combination of the nicotinic acid and other medicines is safe and effective, and a new thought is provided for preparing the medicines for preventing or treating the liver cancer.

The invention relates to the field of medical health, in particular to a breast cancer liver metastasis risk dynamic monitoring and early warning system based on metabonomics, which comprises a data acquisition and preprocessing module for acquiring venous blood samples at three time points of disease progression of a patient, measuring specific metabolite concentration and performing normalization processing; the dynamic feature extraction module calculates a gain index, namely the sum of the change rates of the indexes; the deep learning modeling module uses the first and second deep networks to train sample data in different time periods, and establishes a patient disease prediction model. The comprehensive evaluation module adopts an ROC curve and an AUC value to evaluate the prediction accuracy of the model; the risk early warning module generates a liver metastasis risk early warning signal according to the evaluation result; according to the system, the breast cancer liver metastasis risk is dynamically monitored through metabonomics data acquisition and analysis at multiple time points, the metabolic change trend in disease progression is reflected more accurately, and early warning of the liver metastasis risk is achieved.

The invention relates to the technical field of antitumor drugs, and particularly discloses application and a composition of an iron transporter inhibitor (VIT-2763). The invention provides an application of an iron transporter inhibitor VIT-2763 in preparation of a medicine for preventing and treating tumor metastasis. The iron transporter inhibitor VIT-2763 can obviously inhibit liver metastasis of colorectal cancer and has the potential of being used as a medicine for resisting liver metastasis of colorectal cancer. Meanwhile, the invention further provides a composition for resisting colorectal cancer liver metastasis, the composition comprises the iron transporter inhibitor VIT-2763 and oxaliplatin, and when the iron transporter inhibitor VIT-2763 and the oxaliplatin are combined for use, the drug resistance of colorectal cancer cells to the oxaliplatin can be improved, the sensitivity of liver metastatic colorectal cancer cells to the oxaliplatin is remarkably improved, and the curative effect is good. The treatment effect of resisting colorectal cancer liver metastasis is synergistically enhanced, and the technical problem that an existing treatment means lacks a specific intervention means for colorectal cancer liver metastasis is solved.

The invention relates to application of icaritin combined with one or two of a PD-1 antibody and albumin paclitaxel in preparation of a medicine for treating advanced colorectal cancer, particularly colorectal cancer with liver metastasis. The combined medicine can be applied to medicines for relieving advanced colorectal cancer, particularly colorectal cancer with liver metastasis.

The invention provides application of a PTGIS gene and / or PTGIS protein in preparation of medicines for treating colorectal cancer and preventing and treating liver metastasis of colorectal cancer. The invention proves that PTGIS obviously inhibits colorectal cancer liver metastasis for the first time, and in-vitro and animal experiments show that proliferation, migration and liver metastasis load of colorectal cancer cells can be reduced through overexpression of PTGIS; meanwhile, the immunotherapy effect can be further enhanced by combining the PTGIS and the PD-L1 antibody, and the curative effect is superior to that of a single drug. PTGIS is expected to become a novel intervention target, provides a new molecular regulation thought for immune combined treatment of colorectal cancer liver metastasis, and has theoretical and transformation values.

This invention provides a combination of bile protein biomarkers for predicting liver metastasis of pancreatic cancer and its application. The combination of bile protein biomarkers includes at least MMP9, PRTN3, and S100A12. This application transforms bile, previously considered biological waste, into a high-value diagnostic sample. Based on the differences in bile proteins among patients with benign disease, patients with pancreatic cancer without liver metastasis, and patients with pancreatic cancer with liver metastasis, four optimal biomarker combinations are screened for the first time to establish a method for predicting the risk of pancreatic cancer liver metastasis for early preoperative assessment of pancreatic cancer liver metastasis risk.

The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.

This invention discloses a CD33-blocking humanized antibody and its uses. The CD33-blocking humanized antibody comprises a heavy chain and a light chain; the heavy chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 20; the light chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 21. This invention also discloses a method for preparing the CD33-blocking humanized antibody, obtained by humanizing a rabbit CD33 antibody. Furthermore, it discloses the application of the CD33-blocking humanized antibody in the preparation of drugs for inhibiting liver metastasis of neuroendocrine prostate cancer and small cell lung cancer. The CD33-blocking humanized antibody of this invention exhibits high affinity and high specificity for CD33, and demonstrates excellent therapeutic and inhibitory effects on liver metastasis of neuroendocrine prostate cancer and small cell lung cancer.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

The present invention discloses the use of KAT6A in the preparation of a diagnostic kit for colorectal cancer liver metastasis. This invention, for the first time, discovers the use of the KAT6A gene as a diagnostic marker for CRC liver metastasis in the early diagnosis or prognosis of CRC liver metastasis. Furthermore, the inventors have verified through experiments that, under the same conditions, KAT6A offers superior diagnostic advantages over CEA and AFP, currently discovered potential diagnostic markers for colorectal cancer, avoiding the occurrence of false positives. Therefore, it can be used as an early predictive indicator for colorectal cancer, for early screening and diagnosis of the disease, filling a gap in the early diagnosis of CRC liver metastasis.

The invention belongs to the technical field of organ-like models, and particularly discloses an FET vascularized colorectal cancer organ-like model for evaluating the treatment effect of bevacizumab. The FET vascularized colorectal cancer organoid model is formed by co-culturing human colorectal cancer organoid, vascular endothelial cells (HUVEC-GFP) and hepatic stellate cells (fibroblasts and simulated liver metastasis environment), and is constructed through the steps of separating the human colorectal cancer organoid, preparing a 3D culture support mixture, co-culturing the cells and dynamically culturing. By integrating vascular endothelial cells, hepatic stellate cells and a dynamic flow environment, the limitation of an existing model is overcome, and the treatment effect of bevacizumab is evaluated more accurately. By simulating physiological angiogenesis, liver metastasis microenvironment and hemodynamics, predictability and reliability of drug screening are improved.

The invention belongs to the technical field of disease prognosis and molecular biology, and relates to a flora marker for colorectal cancer liver metastasis diagnosis and liver metastasis risk assessment and application of the flora marker. The marker comprises the following three strains: bifidobacterium bifidum, bacteroides fragilis and bacteroides heparinidolyticus. The method comprises the following steps: acquiring information of microorganisms in excrement of a patient through a high-resolution metagenomics detection technology; a random forest algorithm is utilized to construct a colorectal cancer liver metastasis classification model based on the flora markers, the model can distinguish people without colorectal cancer metastasis and people with liver metastasis and accurately predict high-risk patients with colorectal cancer liver metastasis, and the effect of the model is superior to that of a clinical conventional tumor serum marker. The kit has the advantages of noninvasive detection and high accuracy, and can provide a reliable tool for liver metastasis diagnosis and individualized prognosis management of colorectal cancer patients.

The present invention generally relates to an inhibitor (NPY / Y5R inhibitor) of NPY-5 receptor (Y5R) activation by neuropeptide Y (NPY) for use in the prevention or reduction of metastasis to the liver in a subject. The NPY / Y5R inhibitor is selected from at least one short interference RNA (siRNA) against NPY, at least one Y5R inhibitor, at least one anti-NPY antibody, at least one anti-Y5R antibody, and at least one antisense oligonucleotide (ASO) against NPY.

The application belongs to the technical field of medical image processing and artificial intelligence, and discloses a colorectal cancer liver metastasis risk assessment method and system based on multi-modal fusion. The method comprises the following steps: obtaining preoperative abdominal computed tomography (CT) images and clinical pathological data of a patient; pre-processing the CT images, segmenting a three-dimensional region of interest, and extracting radiomics features, and standardizing the clinical data; inputting the radiomics features into a first prediction model to obtain an imaging score, and inputting the clinical data into a second prediction model to obtain a clinical score; based on a preset fusion strategy, the two scores are weighted and fused, and a comprehensive risk score of postoperative liver metastasis of the patient is output as auxiliary assessment information. The application can accurately assist in assessing the risk of colorectal cancer liver metastasis after surgery by non-invasively and efficiently integrating CT image quantitative features and clinical information, and provides an objective decision-making tool for clinicians to develop individualized diagnosis and treatment plans and follow-up strategies.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido-pyrazine, quinoline, pyrazino-pyridazine, pyrimido-pyrimidine, quinazoline, quinoxaline or cinnoline ring system) which function as inhibitors of DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8 / 19, PI3K, PDGFrA / B, mTOR, WNT, homeodomain-interacting kinases (HIPKs), and / or CMGC kinases leading to inhibition of WNT signaling, and their use as therapeutics for the treatment of Alzheimer's disease, down syndrome, Parkinson's disease, Huntington's disease, diabetes, autoimmune diseases, inflammatory disorders (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer and metastatic colorectal cancer (e.g., metastatic colorectal cancer in the liver)), and other diseases.

The invention provides a composition for reversing drug resistance of a small cell lung cancer hepatic metastatic ferroptosis inducer and application of the composition, and belongs to the technical field of biological medicine. The composition for reversing the drug resistance of the small cell lung cancer hepatometastatic ferroptosis inducer provided by the invention comprises the ferroptosis inducer and a GPX4 inhibitor. The composition can remarkably reverse the drug resistance of a ferroptosis inducer induced by a liver microenvironment, reduce the dosage of the ferroptosis inducer and improve the detection sensitivity and reproducibility through the synergistic effect of improving the lipid peroxidation pressure and reducing the scavenging capacity, and the mechanism specificity is proved to have a good application prospect through a Fer-1 rescue test. The medicine is suitable for small cell lung cancer people with or with high-risk liver metastasis, and a new effective strategy is provided for clinical treatment.

The invention is related to the use of the B3GLCT1 gene and / or the Beta-1, 3- glucosyltransferase protein expressed by the B3GLCT1 gene as a biomarker in the detection of breast tumor-associated liver metastasis.

The application discloses a kind of based on space omics's intestinal cancer metastasis prediction method, device, medium and equipment, method includes: acquisition original multi-omics data, modal alignment and quality control processing are handled, obtain including second spatial transcriptome data, second single-cell RNA sequencing data and second pathology image data pre-processing multi-omics data;Second single-cell RNA sequencing data is based on second spatial transcriptome data and is carried out cross-modal semantic embedding, generates space enhanced expression profile;Second spatial transcriptome data and second pathology image data are carried out multi-scale graph construction, and spatial heterogeneity feature is extracted;Space enhanced expression profile and spatial heterogeneity feature are input into pre-trained metastasis risk prediction model, and output liver metastasis probability space heat map and key driving feature list;Finally generate the clinical prediction report containing high-risk area positioning.The application significantly improves the sensitivity of early metastasis detection by dynamically optimizing spatial resolution and multi-scale feature collaborative modeling.

The invention discloses a medicine for resisting intestinal cancer liver metastasis and application thereof, relates to an anti-cancer medicine and application thereof, and is applied to the field of medicine preparation. The invention aims to provide a low-toxicity second-line therapeutic drug after the first-line therapeutic drug for treating liver metastasis of intestinal cancer is resistant. According to the medicine, sunflower stem marrow polysaccharide is combined with intra-tumor rhodopseudomonas palustris, the material basis for inhibiting tumor proliferation is mainly the metabolite 5-aminolevulinic acid of the rhodopseudomonas palustris, and the material basis for inhibiting intestinal cancer from metastasis to liver is mainly the sunflower stem marrow polysaccharide metabolite acetic acid and long-chain fatty acid. The main mechanism for resisting intestinal cancer liver metastasis is cell apoptosis caused by protein such as ROS damaged mitochondrial membrane and the like generated by activation of 5-ALA; the main mechanism of resisting intestinal cancer liver metastasis is that long-chain fatty acid acts on DNA topoisomerase I to influence cell DNA replication. The method is applied to the pharmaceutical field.